Detalhe da pesquisa
1.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499670
2.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
BMC Cancer
; 16: 651, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27538465
3.
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
BMC Cancer
; 15: 122, 2015 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25886605
4.
B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study.
Front Oncol
; 12: 909505, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35814376
5.
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
BMC Cancer
; 16: 117, 2016 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26887451
6.
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.
Genet Vaccines Ther
; 8: 7, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21040569